Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia

Importance Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trial...

Full description

Saved in:
Bibliographic Details
Main Authors: Jansen, Willemijn J. (Author) , Frölich, Lutz (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: JAMA psychiatry
Year: 2017, Volume: 75, Issue: 1, Pages: 84-95
ISSN:2168-6238
DOI:10.1001/jamapsychiatry.2017.3391
Online Access:Verlag, Volltext: https://doi.org/10.1001/jamapsychiatry.2017.3391
Verlag, Volltext: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2664259
Get full text
Author Notes:Willemijn J. Jansen, PhD; Rik Ossenkoppele, PhD; Betty M. Tijms, PhD; Anne M. Fagan, PhD; Oskar Hansson, MD, PhD; William E. Klunk, MD, PhD; Wiesje M. van der Flier, PhD; Victor L. Villemagne, MD, PhD; Giovanni B. Frisoni, MD; Adam S. Fleisher, MD, MAS; Alberto Lleó, MD, PhD; Mark A. Mintun, MD; Anders Wallin, MD, PhD; Sebastiaan Engelborghs, MD, PhD; Duk L. Na, MD, PhD; Gäel Chételat, PhD; José Luis Molinuevo, MD, PhD; Susan M. Landau, PhD; Niklas Mattsson, MD, PhD; Johannes Kornhuber, MD; Osama Sabri, MD, PhD; Christopher C. Rowe, MD,PhD; Lucilla Parnetti, MD, PhD; Julius Popp, MD; Tormod Fladby, MD, PhD; William J. Jagust, MD, PhD; Pauline Aalten, PhD; Dong Young Lee, MD, PhD; Rik Vandenberghe, MD, PhD; Catarina Resende de Oliveira, MD, PhD; Elisabeth Kapaki, MD, PhD; Lutz Froelich, MD, PhD; Adrian Ivanoiu, MD, PhD; Tomasz Gabryelewicz, MD, PhD; Marcel M. Verbeek, PhD; Páscual Sanchez-Juan, MD, PhD; Helmut Hildebrandt, PhD; Vincent Camus, MD, PhD; Marzena Zboch, MD, PhD; David J. Brooks, MD, PhD; Alexander Drzezga, MD, PhD; Juha O. Rinne, MD, PhD; Andrew Newberg, MD, PhD; Alexandre de Mendonça, MD, PhD; Marie Sarazin, MD, PhD; Gil D. Rabinovici, MD; Karine Madsen, MD, PhD; Milica G. Kramberger, MD, PhD; Agneta Nordberg, MD, PhD; Vincent Mok, MD; Barbara Mroczko, MD; David A. Wolk, MD; Philipp T. Meyer, MD, PhD; Magda Tsolaki, MD, PhD; Amyloid Biomarker Study Group; Philip Scheltens, MD, PhD; Frans R.J. Verhey, MD, PhD; Pieter Jelle Visser, MD, PhD

MARC

LEADER 00000caa a2200000 c 4500
001 1676037152
003 DE-627
005 20230427154506.0
007 cr uuu---uuuuu
008 190905r20182017xx |||||o 00| ||eng c
024 7 |a 10.1001/jamapsychiatry.2017.3391  |2 doi 
035 |a (DE-627)1676037152 
035 |a (DE-599)KXP1676037152 
035 |a (OCoLC)1341242693 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Jansen, Willemijn J.  |e VerfasserIn  |0 (DE-588)1194209009  |0 (DE-627)1676035419  |4 aut 
245 1 0 |a Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia  |c Willemijn J. Jansen, PhD; Rik Ossenkoppele, PhD; Betty M. Tijms, PhD; Anne M. Fagan, PhD; Oskar Hansson, MD, PhD; William E. Klunk, MD, PhD; Wiesje M. van der Flier, PhD; Victor L. Villemagne, MD, PhD; Giovanni B. Frisoni, MD; Adam S. Fleisher, MD, MAS; Alberto Lleó, MD, PhD; Mark A. Mintun, MD; Anders Wallin, MD, PhD; Sebastiaan Engelborghs, MD, PhD; Duk L. Na, MD, PhD; Gäel Chételat, PhD; José Luis Molinuevo, MD, PhD; Susan M. Landau, PhD; Niklas Mattsson, MD, PhD; Johannes Kornhuber, MD; Osama Sabri, MD, PhD; Christopher C. Rowe, MD,PhD; Lucilla Parnetti, MD, PhD; Julius Popp, MD; Tormod Fladby, MD, PhD; William J. Jagust, MD, PhD; Pauline Aalten, PhD; Dong Young Lee, MD, PhD; Rik Vandenberghe, MD, PhD; Catarina Resende de Oliveira, MD, PhD; Elisabeth Kapaki, MD, PhD; Lutz Froelich, MD, PhD; Adrian Ivanoiu, MD, PhD; Tomasz Gabryelewicz, MD, PhD; Marcel M. Verbeek, PhD; Páscual Sanchez-Juan, MD, PhD; Helmut Hildebrandt, PhD; Vincent Camus, MD, PhD; Marzena Zboch, MD, PhD; David J. Brooks, MD, PhD; Alexander Drzezga, MD, PhD; Juha O. Rinne, MD, PhD; Andrew Newberg, MD, PhD; Alexandre de Mendonça, MD, PhD; Marie Sarazin, MD, PhD; Gil D. Rabinovici, MD; Karine Madsen, MD, PhD; Milica G. Kramberger, MD, PhD; Agneta Nordberg, MD, PhD; Vincent Mok, MD; Barbara Mroczko, MD; David A. Wolk, MD; Philipp T. Meyer, MD, PhD; Magda Tsolaki, MD, PhD; Amyloid Biomarker Study Group; Philip Scheltens, MD, PhD; Frans R.J. Verhey, MD, PhD; Pieter Jelle Visser, MD, PhD 
246 3 3 |a Association of cerebral amyloid-beta aggregation with cognitive functioning in persons without dementia 
264 1 |c 2018 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.09.2019 
500 |a Published online November 29, 2017 
520 |a Importance Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials. Objective To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia. Design, Setting, and Participants This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017. Main Outcomes and Measures Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype. Results Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years. Conclusions and Relevance Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited. 
534 |c 2017 
700 1 |a Frölich, Lutz  |d 1956-  |e VerfasserIn  |0 (DE-588)1028327099  |0 (DE-627)730567516  |0 (DE-576)375813160  |4 aut 
773 0 8 |i Enthalten in  |t JAMA psychiatry  |d Chicago, Ill. : AMA, 2013  |g 75(2018), 1, Seite 84-95  |h Online-Ressource  |w (DE-627)734675100  |w (DE-600)2698864-1  |w (DE-576)378915096  |x 2168-6238  |7 nnas  |a Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia 
773 1 8 |g volume:75  |g year:2018  |g number:1  |g pages:84-95  |g extent:12  |a Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia 
856 4 0 |u https://doi.org/10.1001/jamapsychiatry.2017.3391  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2664259  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190905 
993 |a Article 
994 |a 2018 
998 |g 1028327099  |a Frölich, Lutz  |m 1028327099:Frölich, Lutz  |d 60000  |e 60000PF1028327099  |k 0/60000/  |p 32 
999 |a KXP-PPN1676037152  |e 3512071538 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Willemijn J. Jansen, PhD; Rik Ossenkoppele, PhD; Betty M. Tijms, PhD; Anne M. Fagan, PhD; Oskar Hansson, MD, PhD; William E. Klunk, MD, PhD; Wiesje M. van der Flier, PhD; Victor L. Villemagne, MD, PhD; Giovanni B. Frisoni, MD; Adam S. Fleisher, MD, MAS; Alberto Lleó, MD, PhD; Mark A. Mintun, MD; Anders Wallin, MD, PhD; Sebastiaan Engelborghs, MD, PhD; Duk L. Na, MD, PhD; Gäel Chételat, PhD; José Luis Molinuevo, MD, PhD; Susan M. Landau, PhD; Niklas Mattsson, MD, PhD; Johannes Kornhuber, MD; Osama Sabri, MD, PhD; Christopher C. Rowe, MD,PhD; Lucilla Parnetti, MD, PhD; Julius Popp, MD; Tormod Fladby, MD, PhD; William J. Jagust, MD, PhD; Pauline Aalten, PhD; Dong Young Lee, MD, PhD; Rik Vandenberghe, MD, PhD; Catarina Resende de Oliveira, MD, PhD; Elisabeth Kapaki, MD, PhD; Lutz Froelich, MD, PhD; Adrian Ivanoiu, MD, PhD; Tomasz Gabryelewicz, MD, PhD; Marcel M. Verbeek, PhD; Páscual Sanchez-Juan, MD, PhD; Helmut Hildebrandt, PhD; Vincent Camus, MD, PhD; Marzena Zboch, MD, PhD; David J. Brooks, MD, PhD; Alexander Drzezga, MD, PhD; Juha O. Rinne, MD, PhD; Andrew Newberg, MD, PhD; Alexandre de Mendonça, MD, PhD; Marie Sarazin, MD, PhD; Gil D. Rabinovici, MD; Karine Madsen, MD, PhD; Milica G. Kramberger, MD, PhD; Agneta Nordberg, MD, PhD; Vincent Mok, MD; Barbara Mroczko, MD; David A. Wolk, MD; Philipp T. Meyer, MD, PhD; Magda Tsolaki, MD, PhD; Amyloid Biomarker Study Group; Philip Scheltens, MD, PhD; Frans R.J. Verhey, MD, PhD; Pieter Jelle Visser, MD, PhD"]},"recId":"1676037152","person":[{"given":"Willemijn J.","display":"Jansen, Willemijn J.","family":"Jansen","role":"aut"},{"role":"aut","family":"Frölich","display":"Frölich, Lutz","given":"Lutz"}],"physDesc":[{"extent":"12 S."}],"id":{"doi":["10.1001/jamapsychiatry.2017.3391"],"eki":["1676037152"]},"title":[{"title":"Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia","title_sort":"Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"relHost":[{"title":[{"title":"JAMA psychiatry","subtitle":"formerly Archives of general psychiatry","title_sort":"JAMA psychiatry"}],"id":{"issn":["2168-6238"],"eki":["734675100"],"zdb":["2698864-1"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"AMA","dateIssuedDisp":"2013-","dateIssuedKey":"2013","publisherPlace":"Chicago, Ill."}],"recId":"734675100","disp":"Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementiaJAMA psychiatry","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"pages":"84-95","extent":"12","issue":"1","text":"75(2018), 1, Seite 84-95","year":"2018","volume":"75"},"note":["Gesehen am 02.12.2025"],"pubHistory":["70.2013 -"]}],"language":["eng"],"note":["Gesehen am 05.09.2019","Published online November 29, 2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Association of cerebral amyloid-beta aggregation with cognitive functioning in persons without dementia"}]} 
SRT |a JANSENWILLASSOCIATIO2018